BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Drug Development

  Ultragenyx Buys GeneTx to Take Angelman ASO the Distance - Updated

  The buyout comes on the heels of promising Phase I/II results from GTX-102, an antisense oligonucleotide candidate being developed to treat Angelman syndrome.

  July 19, 2022

   · 

  4 min read

   · 

  Tristan Manalac
• 

  Drug Development

  Sanofi, Merck Shut Down Alport Syndrome, Colorectal Cancer Trials

  Sanofi has terminated a development agreement with Regulus in Alport syndrome, while Merck reaches the point of futility in a Phase III colorectal cancer trial.

  July 19, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  Women of Color in Biopharma: Overcoming Barriers and Fighting for a Seat at the Table

  Women of color continue to be trailblazers in the life science industry, proving that they can be just as, if not more, successful than their peers - even if it isn’t always easy.

  July 19, 2022

   · 

  7 min read

   · 

  Rosemary Scott
• 

  Cancer Researchers Find Clues in Blood Samples, Paralogs, Fungus and the Microbiome

  Cancer research facilities are leading the way with methods that will lead to better detection of cancer metastasis, better understanding of cancer cell physiology and greater patient response.

  July 19, 2022

   · 

  5 min read

   · 

  Jazmine Colatriano, M.S.
• 

  Drug Development

  COVID-19 Update: BA.4 and BA.5 Dominate, Long COVID Effects Continue, CDC Considers Novavax

  As the BA.4/BA.5 Omicron subvariants spread, researchers continue to develop COVID-19 therapies and approaches for preventing or treating the disease. For that and more, continue reading.

  July 19, 2022

   · 

  6 min read

   · 

  Mark Terry
• 

  Drug Development

  Roche Inks Potential $1B AAV Vector Deal with Avista for Eye Disease

  Avista Therapeutics inked a partnership deal with Swiss pharma giant Roche to develop AAV gene therapy vectors for eye diseases.

  July 19, 2022

   · 

  4 min read

   · 

  Mark Terry
• 

  Drug Development

  Innovent & Eli Lilly’s Type 2 Diabetes Drug Lowers HbA1c, Scores Early Win

  Innovent Biologics’ Phase II trial of mazdutide, a potential treatment for type 2 diabetes, showed the drug met its primary endpoint by successfully reducing HbA1c levels.

  July 19, 2022

   · 

  1 min read

   · 

  Vanessa Doctor, MS
• 

  Drug Development

  Jazz’s Toehold on Sleep Market Slips with Tentative Avadel FDA Approval

  Avadel and Jazz Pharma, a leader in treating sleep disorders, are locked in a patent dispute. If it receives final FDA approval, Avadel’s Lumryz could challenge Jazz’s market dominance.

  July 19, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Business

  Genetown’s Growing Pains: Eisai Shutters H3 Bio, Biogen Job Cuts have Begun

  The Bay State, home to the busy bio-hub Genetown, is experiencing some growing pains. Companies like Biogen and Eisai (H3 Biomedicine) are reducing their headcount.

  July 19, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  FDA Approves First At-Home Repigmentation Therapy, Opzelura, for Nonsegmental Vitiligo

  The FDA has approved Incyte’s Opzelura as the first and only at-home therapy for repigmentation in nonsegmental vitiligo.

  July 19, 2022

   · 

  3 min read

   · 

  Mark Terry